AbbVie Inc. 8K

AbbVie completed its $10.9 billion acquisition of Apogee Therapeutics, adding a late-stage immunology pipeline while reaffirming 2026 EPS guidance and flagging near-term EPS dilution from the deal.

AbbVie Inc. announced that it has completed its approximately $10.9 billion cash acquisition of Apogee Therapeutics, Inc., paying $135.11 per share and delisting Apogee from NASDAQ as of September 3, 2026. The transaction brings Apogee’s late-stage immunology pipeline into AbbVie, including lead asset zumilokibart (a half-life extended IL-13 monoclonal antibody in Phase 2 for atopic dermatitis) and combination candidate APG273 (zumilokibart plus APG333 targeting IL-13 and TSLP for asthma), which AbbVie expects to develop across multiple inflammatory and immunologic indications. AbbVie reaffirmed its previously issued 2026 full-year adjusted diluted EPS guidance of $13.87–$14.07 and third-quarter 2026 adjusted EPS guidance of $3.84–$3.88, while stating that the Apogee acquisition will be dilutive to adjusted EPS by $0.14 in 2026 and approximately $0.46 in 2027, with accretion beginning in 2032, and highlighted strategic benefits in strengthening its leadership and long-term growth in immunology.

Filing Facts

CIK

1551152

Ticker

ABBV

Form

8K

Source Type

fda

Accession

0001104659-26-104940

Alert Tier

8